Fund HoldingsSaturn V Capital Management LP

Total Portfolio Value
$697.47M
Total Bought
$153.34M
Total Sold
$76.63M
Net Transaction
+$76.71M
Filing Period:
Securities
SharesValue ($K)
Q1 2026
Q2 2026
Change
Q1 2026
Q2 2026
Weight (%)
Change
AMYLYX PHARMACEUTICALS INC(AMLX)4,349,8854,624,101+274,21660,46383,04911.91%+22,585
CANDEL THERAPEUTICS INC(CADL)2,896,5883,303,686+407,09814,19334,0284.88%+19,835
TREVI THERAPEUTICS INC(TRVI)01,052,043+1,052,043019,6212.81%+19,621
IMMIX BIOPHARMA INC(IMMX)3,693,5854,658,429+964,84433,64948,0286.89%+14,380
PHARVARIS N V
COM
1,201,4021,314,122+112,72033,94045,4426.52%+11,503
ALUMIS INC3,202,0752,915,443-286,63270,54282,04111.76%+11,499
SAGIMET BIOSCIENCES INC(SGMT)01,479,918+1,479,918011,4401.64%+11,440
MONOPAR THERAPEUTICS INC(MNPR)345,626311,976-33,65018,93728,8864.14%+9,949
DISC MEDICINE INC(IRON)449,926524,730+74,80428,76838,3795.50%+9,610
ABIVAX SA(ABVX)542,696518,865-23,83160,42969,1449.91%+8,715
ZURA BIO LTD(ZURA)739,9602,101,119+1,361,1594,40312,3971.78%+7,994
JAZZ PHARMACEUTICALS PLC(JAZZ)162,961160,938-2,02330,80838,7815.56%+7,973
VIR BIOTECHNOLOGY INC(VIR)0770,643+770,64307,8531.13%+7,853
CELCUITY INC(CELC)281,904370,318+88,41432,17738,7435.55%+6,566
DYNE THERAPEUTICS INC(DYN)966,6091,057,493+90,88417,52523,4873.37%+5,962
X4 PHARMACEUTICALS INC(XFOR)6,456,6466,973,343+516,69726,66632,5664.67%+5,900
ALTO NEUROSCIENCE INC(ANRO)88,999182,829+93,8302,0014,8250.69%+2,824
VAXCYTE INC(PCVX)824,532852,914+28,38247,91449,5807.11%+1,666
INHIBIKASE THERAPEUTICS INC(IKT)3,863,4453,869,056+5,6116,4917,8541.13%+1,364
SATELLOS BIOSCIENCE INC(MSLE)350,000350,00001,9712,7210.39%+751
OCULIS HOLDING AG(OCS)516,761684,880+168,11913,7419,4991.36%-4,241
INVIVYD INC(IVVD)10,949,0848,392,288-2,556,79614,2347,3211.05%-6,912
OVID THERAPEUTICS INC(OVID)4,166,666663,060-3,503,6069,2501,7840.26%-7,466
COGENT BIOSCIENCES INC(COGT)626,6350-626,63524,1190-24,119
Page 1 of 1
Saturn V Capital Management LP — 13F Holdings — Q2 2026 | TickerTrail